{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:14:16Z","timestamp":1785366856439,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dld.2026.04.017","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:57:16Z","timestamp":1778594236000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term add-on fibrate therapy in Primary Sclerosing Cholangitis: Safety, biochemical response, and disease progression"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7622-6051","authenticated-orcid":false,"given":"E.","family":"Catanzaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Benatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4139-0212","authenticated-orcid":false,"given":"C.","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Perin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.P.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gambato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-191X","authenticated-orcid":false,"given":"P.","family":"Burra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2630-7054","authenticated-orcid":false,"given":"A.","family":"Floreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-9826","authenticated-orcid":false,"given":"R.","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-8664","authenticated-orcid":false,"given":"N.","family":"Cazzagon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.04.017_bib0001","doi-asserted-by":"crossref","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M, Primary sclerosing cholangitis - a comprehensive review. J Hepatol2017 ;67(6):1298\u2013323.","DOI":"10.1016\/j.jhep.2017.07.022"},{"key":"10.1016\/j.dld.2026.04.017_bib0002","doi-asserted-by":"crossref","unstructured":"Rizvi S, Gores GJ, Pathogenesis, diagnosis, and management of cholangiocarcinoma..Gastroenterology 2013 ;145(6):1215\u201329.","DOI":"10.1053\/j.gastro.2013.10.013"},{"key":"10.1016\/j.dld.2026.04.017_bib0003","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol2022 ;77(3):761\u2013806."},{"key":"10.1016\/j.dld.2026.04.017_bib0004","doi-asserted-by":"crossref","unstructured":"Carbone M, Della Penna A, Mazzarelli C, De Martin E, Villard C, Bergquist A, et al. Liver transplantation for primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD)-A European society of organ transplantation (ESOT) consensus statement. Transpl Int2023;36:11729.","DOI":"10.3389\/ti.2023.11729"},{"key":"10.1016\/j.dld.2026.04.017_bib0005","doi-asserted-by":"crossref","unstructured":"Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW, A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis..Gastroenterology 2001 ;121(4):900\u20137.","DOI":"10.1053\/gast.2001.27965"},{"key":"10.1016\/j.dld.2026.04.017_bib0006","doi-asserted-by":"crossref","unstructured":"Lindor KD, Ursodiol for primary sclerosing cholangitis. N Engl J Med1997 ;336(10):691\u20135.","DOI":"10.1056\/NEJM199703063361003"},{"key":"10.1016\/j.dld.2026.04.017_bib0007","doi-asserted-by":"crossref","unstructured":"Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPAR\u03b1-mediated redistribution of ABCB4. J Lipid Res2004 ;45(10):1813\u201325.","DOI":"10.1194\/jlr.M400132-JLR200"},{"key":"10.1016\/j.dld.2026.04.017_bib0008","doi-asserted-by":"crossref","unstructured":"Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HMG, Fibrates suppress bile acid synthesis via peroxisome proliferator\u2013activated receptor-\u03b1\u2013Mediated downregulation of cholesterol 7\u03b1-hydroxylase and sterol 27-hydroxylase expression..ATVB 2001 ;21(11):1840\u20135.","DOI":"10.1161\/hq1101.098228"},{"key":"10.1016\/j.dld.2026.04.017_bib0009","doi-asserted-by":"crossref","unstructured":"Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N, Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol2006 ;41(7):686\u201392.","DOI":"10.1007\/s00535-006-1831-0"},{"key":"10.1016\/j.dld.2026.04.017_bib0010","doi-asserted-by":"crossref","unstructured":"Thomas M, Burk O, Klumpp B, Kandel BA, Damm G, Weiss TS, et al. Direct transcriptional regulation of Human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator\u2013Activated receptor alpha (PPAR \u03b1). Mol Pharmacol2013 ;83(3):709\u201318.","DOI":"10.1124\/mol.112.082503"},{"key":"10.1016\/j.dld.2026.04.017_bib0011","doi-asserted-by":"crossref","unstructured":"Mizuno S, Hirano K, Isayama H, Watanabe T, Yamamoto N, Nakai Y, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepato Biliary Pancreat2015 ;22(10):766\u201370.","DOI":"10.1002\/jhbp.281"},{"key":"10.1016\/j.dld.2026.04.017_bib0012","doi-asserted-by":"crossref","unstructured":"Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French\u2013Spanish experience..Clin Res Hepatol Gastroenterol 2018 ;42(6):521\u20138.","DOI":"10.1016\/j.clinre.2018.06.009"},{"key":"10.1016\/j.dld.2026.04.017_bib0013","doi-asserted-by":"crossref","unstructured":"Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, De La Rosa Rodriguez R, Boyer JL, et al. Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol. Clin Pharma Ther2020 ;108(6):1213\u201323.","DOI":"10.1002\/cpt.1930"},{"key":"10.1016\/j.dld.2026.04.017_bib0014","doi-asserted-by":"crossref","unstructured":"Hatami B, Mosala M, Hassani AH, Ardakani MJE, Gholami S, Zali MR, Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial. Pharmacol Res Perspect2022 ;10(4):e00984.","DOI":"10.1002\/prp2.984"},{"key":"10.1016\/j.dld.2026.04.017_bib0015","doi-asserted-by":"crossref","unstructured":"De Vries E, Bolier R, Goet J, Par\u00e9s A, Verbeek J, De Vree M, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial..Gastroenterology 2021 ;160(3):734\u201343.e6.","DOI":"10.1053\/j.gastro.2020.10.001"},{"key":"10.1016\/j.dld.2026.04.017_bib0016","doi-asserted-by":"crossref","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med2018 ;378(23):2171\u201381.","DOI":"10.1056\/NEJMoa1714519"},{"key":"10.1016\/j.dld.2026.04.017_bib0017","doi-asserted-by":"crossref","unstructured":"Chazouilleres O, Beuers U, Bergquist A, Karlsen TH, Levy C, Samyn M, et al. EASL clinical practice guidelines on sclerosing cholangitis..J Hepatol 2022 ;77(3):761\u2013806.","DOI":"10.1016\/j.jhep.2022.05.011"},{"key":"10.1016\/j.dld.2026.04.017_bib0018","doi-asserted-by":"crossref","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma..Hepatology 2023 ;77(2):659\u2013702.","DOI":"10.1002\/hep.32771"},{"key":"10.1016\/j.dld.2026.04.017_bib0019","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015 ;63(4):971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"10.1016\/j.dld.2026.04.017_bib0020","doi-asserted-by":"crossref","unstructured":"de Vries EM, Wang J, Williamson KD, Leeflang MM, Boonstra K, Weersma R.K, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis..Gut 2018 ;67(10):1864\u20139.","DOI":"10.1136\/gutjnl-2016-313681"},{"key":"10.1016\/j.dld.2026.04.017_bib0021","doi-asserted-by":"crossref","unstructured":"Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis..Mayo Clin Proc 2000 ;75(7):688\u201394.","DOI":"10.1016\/S0025-6196(11)64614-4"},{"key":"10.1016\/j.dld.2026.04.017_bib0022","doi-asserted-by":"crossref","unstructured":"Venkatesh SK, Welle CL, Miller FH, Jhaveri K, Ringe KI, Eaton JE, et al. Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR working group of the international primary sclerosing cholangitis study group. Eur Radiol2022 ;32(2):923\u201337.","DOI":"10.1007\/s00330-021-08147-7"},{"key":"10.1016\/j.dld.2026.04.017_bib0023","doi-asserted-by":"crossref","unstructured":"Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouill\u00e8res O, Arriv\u00e9 L. Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression: ruiz et al..Hepatology 2014 ;59(1):242\u201350.","DOI":"10.1002\/hep.26620"},{"key":"10.1016\/j.dld.2026.04.017_bib0024","doi-asserted-by":"crossref","unstructured":"Grigoriadis A, Imeen Ringe K, Bengtsson J, Baubeta E, Forsman C, Korsavidou-Hult N, et al. Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Rep2022 ;4(12):100595.","DOI":"10.1016\/j.jhepr.2022.100595"},{"key":"10.1016\/j.dld.2026.04.017_bib0025","doi-asserted-by":"crossref","unstructured":"Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology2014 ;146(4):970\u20139.e6.","DOI":"10.1053\/j.gastro.2013.12.030"},{"key":"10.1016\/j.dld.2026.04.017_bib0026","doi-asserted-by":"crossref","unstructured":"Ghonem NS, Ananthanarayanan M, Soroka CJ, Boyer JL, Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology2014 ;59(3):1030\u201342.","DOI":"10.1002\/hep.26894"},{"key":"10.1016\/j.dld.2026.04.017_bib0027","doi-asserted-by":"crossref","unstructured":"Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse..Biochem J 1996 ;314(3):781\u20136.","DOI":"10.1042\/bj3140781"},{"key":"10.1016\/j.dld.2026.04.017_bib0028","doi-asserted-by":"crossref","unstructured":"Floreani A, De Martin S, Treatment of primary sclerosing cholangitis..Dig Liver Dis 2021 ;53(12):1531\u20138.","DOI":"10.1016\/j.dld.2021.04.028"},{"key":"10.1016\/j.dld.2026.04.017_bib0029","doi-asserted-by":"crossref","unstructured":"Gervois P, Fruchart JC, Delerive P, Staels B, Induction of i\u03bab\u03b1 expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-\u03b1 activators..J Biol Chem 2000 ;275(47):36703\u20137.","DOI":"10.1074\/jbc.M004045200"},{"key":"10.1016\/j.dld.2026.04.017_bib0030","doi-asserted-by":"crossref","unstructured":"Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology2014 ;146(4):970\u20139.e6.","DOI":"10.1053\/j.gastro.2013.12.030"},{"key":"10.1016\/j.dld.2026.04.017_bib0031","doi-asserted-by":"crossref","unstructured":"Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol2010 ;45(7):758\u201362.","DOI":"10.1007\/s00535-010-0204-x"},{"key":"10.1016\/j.dld.2026.04.017_bib0032","doi-asserted-by":"crossref","unstructured":"Abdalla SM, Dejman A, Clark V, Levy C, Use of Fenofibrate for patients with primary sclerosing cholangitis..Clin Res Hepatol Gastroenterol 2019;43(3):e33\u20136.","DOI":"10.1016\/j.clinre.2018.11.017"},{"key":"10.1016\/j.dld.2026.04.017_bib0033","doi-asserted-by":"crossref","unstructured":"Carrion AF, Lindor KD, Levy C, Safety of fibrates in cholestatic liver diseases. Liver Int2021 ;41(6):1335\u201343.","DOI":"10.1111\/liv.14871"},{"issue":"1","key":"10.1016\/j.dld.2026.04.017_bib0034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial","volume":"84","author":"Levy","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.04.017_bib0035","doi-asserted-by":"crossref","unstructured":"Ponsioen CY, Lindor KD, Mehta R, Dimick-Santos L, Design and endpoints for clinical trials in primary sclerosing cholangitis..Hepatology 2018;68(3):1174\u201388.","DOI":"10.1002\/hep.29882"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:37:02Z","timestamp":1783168622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826007231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1590865826007231"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.017","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term add-on fibrate therapy in Primary Sclerosing Cholangitis: Safety, biochemical response, and disease progression","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}